背景:已观察到2型糖尿病与肌肉减少症之间存在双向关系,尤其是老年人。虽然以前的研究报道,imeglimin改善线粒体功能,他们尚未评估其对2型糖尿病患者肌肉力量的影响。因此,本研究的目的是研究伊美美素对2型糖尿病患者肌力的影响。
方法:在这项前瞻性队列研究中,我们招募了同意的2型糖尿病患者(20~75岁).瘦体重变化(LBM),脂肪量,股四头肌肌力,从基线(第0周)到第24周的握力进行了评估,并比较了使用伊米霉素治疗的患者(I组)和未服用伊米霉素的患者(对照组,C组)。
结果:我们招募了27名接受伊美素治疗的患者(I组)和29名对照组(C组),其中50人完成了研究(I组:n=23;C组:n=27)。LBM的变化,全身脂肪量,两组从基线到第24周的骨骼肌指数没有显著差异.然而,从基线到第24周,I组的股四头肌膝关节伸展强度变化百分比明显高于C组(13±19%和2.1±14%,p=0.022)。相反,握力变化百分比差异不显著。多变量分析表明,使用imeglimin与股四头肌膝关节伸展力量的百分比变化显着相关,独立于年龄,性别,身体质量指数,和骨骼质量指数(β=0.325,p=0.0014)。
结论:Imeglimin对2型糖尿病患者的肌力有积极影响,而不改变LBM。因此,imeglimin对人体骨骼肌有独特的作用。需要进一步的随机对照试验来验证这些发现。
背景:这项研究在大学医院医疗信息网络(UMIN,UMIN000054715)。
BACKGROUND: A bidirectional relationship has been observed between type 2 diabetes mellitus and sarcopenia, especially among older adults. While previous studies have reported that
imeglimin improves mitochondrial function, they have not assessed its effects on muscle strength in patients with type 2 diabetes. Therefore, we aimed to investigate the effects of
imeglimin on muscle strength in patients with type 2 diabetes.
METHODS: In this prospective cohort study, we recruited consenting patients with type 2 diabetes (20-75 years). Changes in lean body mass (LBM), fat mass, quadriceps muscle strength, and grip strength from baseline (week 0) to week 24 were evaluated and compared between patients treated with imeglimin therapy (group I) and those who did not take
imeglimin (controls, group C).
RESULTS: We recruited 27 patients treated with
imeglimin (group I) and 29 controls (group C), and 50 of them completed the study (group I: n = 23; group C: n = 27). The change in LBM, total body fat mass, or skeletal muscle index from baseline to week 24 did not differ significantly between the two groups. However, group I exhibited a significantly higher percent change in quadriceps knee extension strength from baseline to week 24 than group C (13 ± 19% and 2.1 ± 14%, p = 0.022). Conversely, the difference in percent change in grip strength was not significant. Multivariable analysis showed that imeglimin use was significantly associated with a percent change in quadriceps knee extension strength, independent of age, sex, body mass index, and skeletal mass index (β = 0.325, p = 0.0014).
CONCLUSIONS: Imeglimin positively affected muscle strength in patients with type 2 diabetes without altering LBM. Therefore,
imeglimin exerts a unique effect on skeletal muscles in humans. Further randomized controlled trials are needed to validate these findings.
BACKGROUND: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000054715).